Compare NetEase Inc (NTES) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs BIO-TECHNE Corp — how do they compare? NetEase Inc trades at $116.04 (market cap $76.85B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: NetEase Inc is far larger — about 6.8× BIO-TECHNE Corp's market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals.
| NTES | TECH | |
|---|---|---|
Market Cap | $76.85B | $11.34B |
Sector | Media | Health |
52-Week High | $159.34 | $72.48 |
52-Week Low | $109.26 | $43.31 |
Enterprise Value | $52.59B | $11.36B |
Dividend Yield | 2.45% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.45, up 0.13% on the day, with a bearish technical signal from moving averages and mixed earnings performance including a Q2 2026 EPS miss. The company maintains strong profitability with a 27.88% net income margin and robust cash flow, though net cash flow turned negative in 2025. Recent news highlights dividend growth and international expansion efforts amid competitive pressures.
The stock presents a valuation opportunity with a P/E of 15.93 below sector averages, supported by an 81.82% analyst buy rating. Key risks include earnings volatility and heavy investing outflows, but solid fundamentals and global growth initiatives offer long-term upside potential for patient investors.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
